Evogene Q2 EPS $(0.63) Misses $(0.27) Estimate, Sales $347.000K Beat $325.000K Estimate
Evogene (NASDAQ:EVGN) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.27) by 133.33 percent. This is a 26 percent decrease over losses of $(0.50) per share from the same
Evogene lost more money per share than experts thought it would, even though it sold more stuff than expected. When a company loses more money than people predicted, it can make investors worry about whether the business is heading the right way.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.